Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Mitra Mosharraf, M Pharm, PhD, MBA (she/her/hers)

CSO
HTD Biosystems

Dr. Mosharraf has 24 years of experience in biotech drug development. At Pfizer/Pharmacia (Sweden), she contributed to development of lyophilized combination products in dual chamber syringes. In 2005, she moved to the San Francisco Bay Area, joining HTD Biosystems as Chief Scientific Officer, where she developed formulations for vaccines and biotherapeutics. In 2017, she became Director of Drug Product Development at Santen, leading ophthalmic biologic development for retinal diseases. In 2019, she co-founded Engimata Inc. to tackle vaccine instability in the cold chain.
Her innovative work has resulted in six patents and over 15 scientific publications. An active AAPS member, she has held various leadership roles, including the 2024 Vice Chair of the Nanotechnology Community.
Dr. Mosharraf holds a PhD in Pharmaceutical Sciences and an MS in Pharmacy from Uppsala University, and an MBA from MIT Sloan School of Management, with certificates in Business Analytics and AI in Biotech. Licensed as a pharmacist by the Swedish National Board of Health & Welfare, she is trilingual and has lived and worked in Asia, Europe, and the U.S., adding a global perspective to her expertise.

Disclosure information not submitted.

Presentation(s):